Global Healthcare Trends Will Expand Access To Advanced Therapies

Published
18 Jul 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$123.75
7.8% undervalued intrinsic discount
20 Aug
US$114.15
Loading
1Y
48.3%
7D
-3.3%

Author's Valuation

US$123.8

7.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 8.15%

Shared on30 Apr 25
Fair value Increased 0.37%

AnalystConsensusTarget has increased revenue growth from 2.8% to 3.2%.

Shared on23 Apr 25
Fair value Increased 1.19%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on16 Apr 25
Fair value Increased 0.90%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.036%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 5.61%

AnalystConsensusTarget has increased revenue growth from 2.2% to 2.6% and increased profit margin from 26.6% to 29.6%.